FDA to Review Peptides for Addition to 503A Bulks List Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Regulatory Updates on Compounded Peptides New Drug Loft and VLS Pharmacy Industry Update: Interim 503A and 503B Bulks Lists New Revisions